Actinium Pharmaceuticals, Inc. — Director's Dealing 2025

Apr 3, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Actinium Pharmaceuticals, Inc. (ATNM)
CIK: 0001388320
Period of Report: 2025-03-31

Reporting Person: Shetty Ajit (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-03-31	Stock Option (Right to Buy)	$47.40	D	2500	Disposed	2027-03-28	Common Stock (2500)	Direct
2025-03-31	Stock Option (Right to Buy)	$23.49	D	2500	Disposed	2028-07-13	Common Stock (2500)	Direct
2025-03-31	tock Option (Right to Buy)	$6.96	D	8333	Disposed	2029-07-12	Common Stock (8333)	Direct
2025-03-31	Stock Option (Right to Buy)	$9.55	D	8333	Disposed	2030-08-12	Common Stock (8333)	Direct
2025-03-31	Stock Option (Right to Buy)	$6.07	D	18351	Disposed	2031-09-01	Common Stock (18351)	Direct
2025-03-31	Stock Option (Right to Buy)	$4.96	D	72156	Disposed	2032-07-01	Common Stock (72156)	Direct
2025-03-31	Stock Option (Right to Buy)	$5.00	D	70311	Disposed	2033-12-28	Common Stock (70311)	Direct

Footnotes

F1: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration.